RE:RE:Beam Therapeutics Phase 1 CAR-T study placed on hold by FDAAugust 30, 2022 - "The FDA’s concerns about BEAM-201 are multi-faceted but include questions about the company’s gene-editing technology."
"Evidently, the company’s editing aspirations have been more difficult to execute than expected. In addition to addressing regulators’ questions, the company reported ealier in August that more edits than expected are necessary to make its cell therapies fully allogeneic. The revelation means that the company will no longer be nominating a second CAR-T candidate in 2022. "
https://www.fiercebiotech.com/biotech/beam-sheds-more-light-clinical-hold-slapped-gene-edited-car-t